RNA sequencing of BT474 cells treated with trastuzumab or trastuzumab + pertuzumab and BT474-derived cells resistant to trastuzumab or trastuzumab + pertuzumab

We sequenced untreated BT474 cells, BT474 cells treated for three days with trastuzumab or trastuzumab + pertuzumab, as well as two BT474-derived trastuzumab-resistant pools and two BT474-derived trastuzumab + pertuzumab resistant pools. Resistant pools were generated by culturing BT474 cells in gradually increasing doses of trastuzumab and trastuzumab + pertuzumab over the course of several months and continually maintained in drug. Overall design: Examination of mRNA profiles of 1) BT474 cells 2) BT474 cells treated for three days with trastuzumab 3) BT474 cells treated for three days with trastuzumab + pertuzumab 4) two trastuzumab-resistant cell pools 5) two trastuzumab+pertuzumab resistant cell pools